We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
24 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Nelarabine-Reach has been approved to treat patients with relapsing /refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for NELARABINE-REACH nelarabine 250 mg/50 mL solution for infusion vial.
-
Prescription medicine decision summaryNelarabine-Reach (nelarabine) is an anti-cancer drug approved for the treatment of relapsing/refractory T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma.
-
Prescription medicine registrationActive ingredients: nelarabine.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CYCLOPHOSPHAMIDE-REACH cyclophosphamide (as monohydrate) 1000 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CYCLOPHOSPHAMIDE-REACH cyclophosphamide (as monohydrate) 500 mg powder for injection vial.
-
Jan-2024Prescription medicine evaluationActive ingredient: dexrazoxane.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CARBOPROST-REACH carboprost (as trometamol) 250 microgram/1mL solution for injection vial.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ROMIDEPSIN-REACH 10mg powder for injection vial, and solvent for reconstitution vial.